Evidence map›Paper›PMID 33615642›Full record

Trial reportEuropean journal of heart failure2021

Effect of dapagliflozin on anaemia in DAPA-HF.

Kieran F Docherty, James P Curtain, Inder S Anand, Olof Bengtsson, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski and 7 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Canagliflozin and iron metabolism in the CREDENCE trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · on this map
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 9 countries.

Kieran F DochertyBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
James P CurtainBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Inder S AnandDepartment of Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, USA.
Olof BengtssonAstraZeneca R&D, Gothenburg, Sweden.
Silvio E InzucchiSection of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Lars KøberRigshospitalet Copenhagen, University Hospital, Copenhagen, Denmark.
Mikhail N KosiborodSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA.
Anna Maria LangkildeAstraZeneca R&D, Gothenburg, Sweden.
Felipe A MartinezNational University of Cordoba, Cordoba, Argentina.
Piotr PonikowskiWroclaw Medical University, Wroclaw, Poland.
Marc S SabatineTIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Morten SchouDepartment of Cardiology, Gentofte University Hospital, Copenhagen, Denmark.
Mikaela SjöstrandAstraZeneca R&D, Gothenburg, Sweden.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Pardeep S JhundBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID 0000-0002-6317-3975
DAPA-HF Investigators and Committees
University of Glasgow · GBAstraZeneca (Netherlands) · NLBrigham and Women's Hospital · USCopenhagen University Hospital · DKGentofte Hospital · DKUniversidad Nacional de Córdoba · ARUniversity of Minnesota · USUNSW Sydney · AUWroclaw Medical University · PLYale University · US

Funding

British Heart Foundation is a national charity funding cardiovascular research in the UK RE/18/6/34217
6 · The paper itself

Abstract

aimAnaemia is common in heart failure and associated with worse outcomes. We examined the effect of dapagliflozin on correction of anaemia in patients with heart failure (HF) and reduced ejection fraction in DAPA-HF. We also analysed the effect of dapagliflozin on outcomes, according to anaemia status at baseline. METHODS AND

resultsAnaemia was defined at baseline as a haematocrit <39% in men and <36% in women. Resolution of anaemia was defined as two consecutive haematocrit measurements above these thresholds at any time during follow-up. The primary outcome was a composite of worsening HF (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. Of the 4744 patients randomized in DAPA-HF, 4691 had a haematocrit available at baseline, of which 1032 were anaemic (22.0%). The rate of the primary outcome was higher in patients with anaemia (16.1 per 100 person-years) compared with those without (12.9 per 100 person-years). Anaemia was corrected in 62.2% of patients in the dapagliflozin group, compared with 41.1% of patients in the placebo group. The effect of dapagliflozin on the primary outcome was consistent in anaemic compared with non-anaemic patients [hazard ratio (HR) 0.68, 95% confidence interval (CI) 0.52-0.88 vs. HR 0.76, 95% CI 0.65-0.89; interaction P = 0.44]. Similar findings were observed for cardiovascular death, HF hospitalization, and all-cause mortality. Patients with resolution of anaemia had better outcomes than those in which anaemia persisted.

conclusionPatients with anaemia had worse outcomes in DAPA-HF. Dapagliflozin corrected anaemia more often than placebo and improved outcomes, irrespective of anaemia status at baseline.

Indexed as

AnemiaHeart FailureBenzhydryl CompoundsFemaleGlucosidesHumansMaleStroke VolumeBenzhydryl CompoundsdapagliflozinGlucosidesAnaemiaClinical trialsHeart failure with reduced ejection fractionSodium-glucose co-transporter 2 inhibitor

Identifiers

PMID33615642
PMCPMC11497230
OpenAlexW3132325778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.